Sarcoidosis frequently resolves. Resolution rates of sarcoidosis vary depending on
the population that is studied. A Spanish sarcoidosis cohort of 193 patients reported
that 160 (83%) achieved resolution [
[1]
]. These authors and others [
[2]
] have found that resolution of sarcoidosis usually occurs within the first two years
after diagnosis, and resolution of active disease beyond two years only occurs 10%
of the time. However, data from Japanese and Swedish sarcoidosis cohorts found increasing
rates of chest radiograph resolution for five years, with few additional resolutions
beyond that point [
3
,
4
,
5
]. The cumulative 5-year chest radiograph resolution rate was 60% and 80% in the Japanese
and Swedish sarcoidosis cohorts respectively [
3
,
4
,
5
]. An analysis of 818 British sarcoidosis patients found that slightly more than half
had resolution of disease within 2 years [
[6]
]. The World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG)
Task Force of 10 sarcoidosis referral centers found that one-quarter of their sarcoidosis
patients did not require treatment for more than one year [
[7]
]. Regardless of these differing resolution rates that were confounded by varying
definitions of a sarcoidosis resolution, it is clear that a sizeable proportion of
sarcoidosis patients experience termination of their disease.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Respiratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Clinical factors predicting persistence of activity in sarcoidosis: a multivariate analysis of 193 cases.Respiration. 1994; 61: 219-225
- Presentation of sarcoidosis and outcome of pulmonary changes.Dan. Med. Bull. 1982; 29: 27-32
- Clinical courses and prognoses of pulmonary sarcoidosis.Curr. Opin. Pulm. Med. 1999; 5: 293-298
- Sarcoidosis: epidemiology and prognosis. A 15-year European study.Am. Rev. Respir. Dis. 1984; 130: 29-32
- The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsy-proven cases.Sarcoidosis Vasc. Diffuse Lung Dis. 2000; 17: 158-166
- Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients.Q. J. Med. 1983; 52: 525-533
- Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force.Sarcoidosis Vasc. Diffuse Lung Dis. 2011; 28: 56-64
- Acute pulmonary exacerbations of sarcoidosis.Chest. 2012; 142: 827-836
- Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy.Chest. 1997; 111: 623-631
- Presenting characteristics as predictors of duration of treatment in sarcoidosis.QJM. 2006; 99: 307-315
- Regression of sarcoidosis during pregnancy: case report and review of the literature.Mediterr J Rheumatol. 2020; 31: 416-420
- Specific antigen(s) in sarcoidosis: a link to autoimmunity?.Eur. Respir. J. 2016; 47: 707-709
- Proteomic profiling reveals autoimmune targets in sarcoidosis.Am. J. Respir. Crit. Care Med. 2015; 191: 574-583
- Bacterial antigens and molecular mimicry: the bridging common problematic link in the pathogenesis of sarcoidosis and sarcoid-like reactions: isn't it time to wake up?.Wien Med. Wochenschr. 2014; 164: 260-262
- Durible medication-free remission of sarcoidosis following discontinuation of anti-tumor necrosis factor-alpha therapy.Respir. Med. 2022; 206: 107055
- Clinical outcomes in sarcoidosis after cessation of infliximab treatment.Respirology. 2009; 14: 522-528
- Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis.Eur. Respir. J. 2014; 43: 602-609
Article info
Publication history
Published online: November 24, 2022
Publication stage
In Press Journal Pre-ProofFootnotes
☆The authors takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
